Management
John Lai
CEO, President & Director
Mr. Lai has been a director and senior executive officer since March 2014, serving in various capacities that include Principal Financial Officer, President and CEO; and serving as our Chief Executive Officer from March 2014 to May 2017 and June 2019 to present. From March 2012 to April 2016, Mr. Lai also was Chief Executive Officer and a director of Blue Earth Resources, Inc., a small public company which acquired and managed working interests in producing oil and gas leases in Louisiana. Mr. Lai has over thirty years of senior executive and operational management and financial experience while holding key executive positions with several public companies in various industries.
In 1992 Mr. Lai founded and until December 2012 was the principal owner and President of Genesis Capital Group, Inc., which provided significant consulting services to many public and private companies in the powersports, technology and other industries, while advising its clients in corporate development, mergers and acquisitions, and private and public capital-raising through equity offerings. Mr. Lai’s role as a co-founder of the company and his many years of experience as a chief executive officer of many public or private companies are material factors regarding his qualifications to serve on our Board of Directors.
Garry Lowenthal
Chief Financial Officer
Mr. Lowenthal has served as PetVivo Chief Financial Officer since March 2024. He has over 25 years of experience in senior operations and key finance management positions, both with private and public companies. He has developed a substantial background with equity capital raising transactions while managing both private placements and public offerings for various corporations. Mr. Lowenthal has vast financial and corporate management experience, including performing the functions as the Managing Partner of Security First International, Inc., a CFO advisory and management consulting firm, and taking on the responsibilities of a director, Executive Vice President and Chief Financial Officer of Fision Corporation (OTCQB: FSSN). Furthermore, Mr. Lowenthal has served on the national board of Financial Executives International (FEI), a premier professional association for CFOs and other senior financial executives. He has also served as President of the Twin Cities Chapter of FEI and, in the past, as chairman of FEI's national technology committee. Mr. Lowenthal has been on the Alumni Advisory Board of the Carlson School of Management at the University of Minnesota where he graduated with a master's degree in Taxation and Finance and a Bachelor's of Science in Business degree in Accounting and an Associates in Liberal Arts degree from the University of Minnesota. He has also served as a District Chairman for the Boy Scouts of America and serves on the President’s Cabinet for the local Council. Mr. Lowenthal is also a past President and Director for Kiwanis International in his local community club. As an operational CFO, along with his financial reporting and regulatory expertise, Mr. Lowenthal further understands the world of corporate governance, through his experiences as serving as a fiduciary director. Finally, Mr. Lowenthal’s experiences working for two of the largest CPA/Consulting firms, PricewaterhouseCoopers (PwC) and Deloitte, with various client engagements in diverse industries, allows him to bring a unique perspective as an advisor to Boards of Directors of public companies.
John Dolan
Chief Business Development Officer & General Counsel
Mr. Dolan has been working with the Company as a director and/or an officer since March 2014. He has served as our Chief Financial Officer from March 2014 to November 2017, General Counsel since October 2019 and Chief Business Development Officer since August 2021. Mr. Dolan also has served as a director for a number of early stage companies, such as TERRACOH, Inc. and Traust Structured, LLC. Mr. Dolan was also a shareholder in the intellectual property group of the Minneapolis law firm of Fredrikson & Byron, where he specialized in securing and protecting domestic and foreign patent and other IP rights, as well as providing counsel to various clients involving mergers and acquisitions, private equity and other related corporate matters.
During the past five years, Mr. Dolan has also provided consulting services to several early stage companies on all aspects of IP asset protection as well as new technology and corporate development. His extensive career in intellectual property development and corporate counsel includes serving as a patent examiner with the U.S. Patent and Trademark Office (USPTO).
Josh Wilhelm
Vice President of R&D and Clinical Trials
Mr. Wilhelm was the Director of Islet Manufacturing and R&D at the Schulze Diabetes Institute (“SDI”), coordinating the islet isolation and research activities of the "Isolation Core". As the Director of Manufacturing at SDI, Mr. Wilhelm supervised all cGMP manufacturing, process engineering, and quality systems. He further assumed the role at SDI of lead supervisor for human clinical islet manufacturing, managed both clinical and pre-clinical activities of the team and pursued research related to understanding and improving islet isolation yields and islet graft function. Mr. Wilhelm obtained his M.S. in Biomedical Engineering from the University of Minnesota in 2004 and entered industry to explore the real-world application of biomaterials and cell, tissue, and gene therapies for Medtronic, Inc and several local medical device and biotechnology start-ups.
Bryan Monninger
Vice President of Sales & Distributor Relations
Mr. Monninger has over 20+ years within the animal industry, focused in the areas of Sales and Marketing with growing levels of responsibility. Experiences include Hill’s Pet Nutrition Science Diet and Prescription Diet brands, Novus International for large animal feed additives, and Lintbells/YuMOVE in the companion animal joint supplement category. This range of roles has allowed for managing large existing businesses, bringing significant scientific innovation to the profession, as well as building a veterinary business from zero. Bryan has successfully built and developed both veterinary sales and marketing teams delivering market share, revenue, and profit growth to multiple businesses. Bryan has a strong passion for the veterinary profession and the animal industry in its special mission to further the human/animal bond.
Andrea Cranston
Vice President of Marketing
Mrs. Cranston is a strategic marketing professional with more than a decade of experience across animal health, consumer technology, financial services, real estate and full-service agency environments. Her background includes brand positioning, go-to-market strategic planning, demand generation, paid and organic media strategy, CRM and marketing automation, and cross-functional collaboration. She has led integrated marketing initiatives designed to support measurable growth, strengthen brand presence, and align strategy with scalable execution. Andrea is driven by a passion for helping animals live healthier, more comfortable lives, and is committed to advancing solutions that support long-term wellness and quality of life.
Dr. Kirsty Husby, DVM, MS, MBA, DACVS (LA)
Senior Technical Service Veterinarian
Dr. Husby received her BS in Animal Science and Doctor of Veterinary Medicine degrees from Iowa State University. She completed an internship and Clinical Fellowship (equine surgery) at the University of Missouri, followed by a large animal surgical residency and Master of Veterinary Science degree at Oregon State University.
She achieved Diplomate status, becoming board certified in large animal surgery (DACVS) in 2019. She served as Clinical Instructor and as a large animal emergency clinician at the Oregon State University School of Veterinary Medicine for several years, followed by time as an in-house equine surgeon with a private equine clinic.
Dr. Kirsty is currently a locum surgeon in Corvallis, Oregon, following her time as a small animal veterinarian and Medical Director at Cascade Animal Hospital.
Dr. Juli Goldstein, DVM, CHPV
Technical Service Veterinarian
Dr. Juli Goldstein received her Bachelor of Science in Zoology and her Doctor of Veterinary Medicine degree from Auburn University and is a dual recipient of the Young Alumni Achievement Award from the College of Science and Mathematics and the College of Veterinary Medicine. Most recently, she also received her certification from the International Association of Animal Hospice and Palliative Care (CHPV). Her experience spans across varied disciplines including small animal emergency and general practice, marine wildlife medicine, clinical research, and laboratory animal care across North America and international locations.
Previously, serving as an associate research professor and chief clinician for Florida Atlantic University, Dr. Juli has contributed to more than 50 peer-reviewed publications and conducted extensive field research, including the medical management of health and environmental risk assessments involving more than 400 wild dolphins. Her expertise extends beyond traditional veterinary practice, gaining widespread recognition for her work with 'Winter' and 'Hope,' the dolphins featured in Warner Brothers' "Dolphin Tale" films, where she appeared as herself.
Currently, Dr. Juli serves as a consulting veterinarian for NOAA Fisheries and accredited facilities, where she advises on the health and welfare of marine mammals. She also serves as an appointed member of the Auburn University College of Veterinary Medicine Alumni Advisory Council.
Board of Directors
Mr. Costantino is a retired CPA and former senior executive who has served as Chief Executive Officer, Chief Operating Officer and Chief Financial Officer of large corporations. He is currently a part time financial consultant, investor and a current member of the Board of Directors of 4 Yamaha Motor Finance subsidiaries. His most recent executive position was a dual role of Senior Executive Vice President– Chief Financial Officer and Chief Operating Officer of NASDAQ listed WFS Financial, Inc., an automotive and commercial finance company and concurrently as Executive Vice President – Chief Financial Officer and Chief Operating Officer of NYSE listed Westcorp Inc, an OTS regulated bank. He was responsible for operations and all financial areas including SEC filings, analyst interaction, earnings calls, and treasury of both companies. Mr. Costantino played a key role in the negotiation and ultimate sale of both companies to Wachovia (Wells Fargo) for $3.9 billion.
Prior to that, he was President & CEO and member of the Board of Directors of Mitsubishi Motors Credit of America, Inc - an automotive finance company with over $10 billion in assets, where he guided the company to profitability and ultimately negotiated the sale of the company’s assets to Merrill Lynch. Prior to that, he served for 17 years at various escalating management positions of Volvo Cars of North America and Volvo North America including being SVP & CFO of both the automotive parent company and the captive finance company. He was integral to the successful relocation of the company from the East Coast to California, as part of the creation of the Premier Auto Group after Ford Motor Company acquired Volvo.
Robert Rudelius
Director
Mr. Rudelius is the CEO and Managing Director of Noble Ventures, LLC, a company he founded in 2001 that provides advisory and consulting services to early and mid-stage companies in the information technology, communications, medical technology and social e-commerce industries. From April 1999 through May 2001, when it was acquired by StarNet L.P., Mr. Rudelius was the founder, Chairman and CEO of Media DVX, Inc., a start-up business that provided a satellite-based, IP-multi casting alternative to transmitting television commercials via analog videotapes to television stations, networks and cable television operators throughout North America.
From April 1998 to April 1999, Mr. Rudelius was the President and COO of Control Data Systems, Inc., during which time Mr. Rudelius reorganized and re-positioned the software company as a professional technology services company, resulting in the successful sale of the company to British Telecom. From October 1995 through April 1998, Mr. Rudelius was the founding Managing Partner of AT&T; Solution’s Media, Entertainment &; Communications industry group.
From January 1990 through September 1995, Mr. Rudelius was a partner in McKinsey &; Company’s Information, Technology and Systems practice, during which time he headed the practice in Japan and the United Kingdom. Mr. Rudelius began his career at Arthur Andersen &; Co. where he was a leader in the firm’s financial accounting systems consulting practice. Mr. Rudelius has served as a member of the Axogen, Inc. (AXGN) Board of Directors since September 2010, where he is chairman of the audit committee and a member of the compensation committee.
Dr. Jaime Pickett
Director
Dr. Pickett is a veterinary healthcare executive, entrepreneur and board leader with more than 20 years of experience in animal health, multi-site operations, corporate strategy, business development and product commercialization. She currently serves as Chief Medical Officer of EQUUSIR USA and as Advising Chief Medical Officer and a board member of Alexander International Innovations, providing clinical, regulatory, commercialization and strategic guidance for emerging medical and animal-health technologies. She also serves on the Board of Chief Veterinary Medical Officers and is a Scenthound multi-unit franchisee.
From 2023 to 2026, Dr. Pickett held executive leadership roles with Hannah Pet Hospitals, including Chief Executive Officer, President, board member and Chief Strategy Officer. From 2017 to 2022, she served as Chief Veterinary Officer and Senior Vice President of Pet Paradise and as Chief Operating Officer of its subsidiary, NewDay Veterinary Care. In these executive leadership roles, she led veterinary and operational strategy across more than 55 pet resorts and veterinary hospitals in over 15 states, directed teams of more than 100 veterinary professionals, and was instrumental to the organization’s strong enterprise revenue. Her experience also includes veterinary practice ownership, multi-site expansion, mergers and acquisitions evaluation, and telehealth implementation.
Dr. Pickett earned her Doctor of Veterinary Medicine from the University of Florida College of Veterinary Medicine, an MBA from St. George’s University and a Bachelor of Arts from Johns Hopkins University. She also completed the Global C-Suite Program through Wharton Executive Education at the University of Pennsylvania. She is a member of the American Veterinary Medical Association and served for nine years on the University of Florida College of Veterinary Medicine Admissions Committee.
Michael Handley
Director
Josh Ruben
Director
Rob Costantino
Director
Mr. Handley is a life sciences executive and board director with more than 25 years of experience in the biotechnology, pharmaceutical, and medical device industries. He has raised more than $700 million in public and private capital, supported more than 80 global product launches, and led or contributed to transactions with an aggregate value exceeding $4 billion. His experience includes corporate strategy and governance, capital markets, investor relations, mergers and acquisitions, licensing, clinical development, regulatory affairs, commercialization, and global operations.
Mr. Handley served as Chief Executive Officer and a director of Valion Bio, Inc. (Nasdaq: VBIO) from March to August 2026 and as its Chief Operating Officer and President of Biopharma from February 2025 to March 2026. From July 2021 to February 2025, he served as President, Chief Executive Officer, and Chairman of Statera Biopharma, Inc. (OTC: STAB). From July 2019 to March 2020, he served as Chief Executive Officer and a director of Immune Therapeutics, Inc. (OTC: IMUN). From 2012 to 2018, Mr. Handley served as Chief Executive Officer and a director of Armis Biopharma, a privately held development-stage healthcare company, where he oversaw operations, corporate strategy, global product approvals, intellectual property, commercialization, business development, and financing. Mr. Handley helped found Vessix Vascular, Inc. in 2011 and served as its Vice President of Clinical, Quality, and Regulatory until its acquisition by Boston Scientific Corporation for approximately $435 million in 2012. From 2010 to 2011, he served as Global Head of Regulatory at Acclarent, Inc. until its acquisition by Johnson & Johnson for approximately $785 million. Earlier in his career, he held senior executive positions at Spectranetics Corporation (Nasdaq: SPNC) and Accelapure Corporation and held consulting and drug-development roles at Genentech, Inc. (Nasdaq: DNA), Amgen Inc. (Nasdaq: AMGN), and Gliatech Inc. (Nasdaq: GLIA).
Mr. Handley graduated cum laude from Colorado State University with a B.S. in Molecular Biology and Physiology and minors in Chemistry and Neuroanatomy. He attended the Executive MBA program at Pepperdine University and completed the Global C-Suite Program at the Wharton School of the University of Pennsylvania. Mr. Handley has served on corporate and nonprofit boards, taught in Colorado State University’s Regulatory Affairs Program, lectured at Drexel University’s LeBow College of Business, and is an inventor and author of issued patents, published patent applications, and peer-reviewed scientific publications.
John Lai
CEO, President and Director
Mr. Lai has been a director and senior executive officer since March 2014, serving in various capacities that include Principal Financial Officer, President and CEO; and serving as our Chief Executive Officer from March 2014 to May 2017 and June 2019 to present. From March 2012 to April 2016, Mr. Lai also was Chief Executive Officer and a director of Blue Earth Resources, Inc., a small public company which acquired and managed working interests in producing oil and gas leases in Louisiana. Mr. Lai has over thirty years of senior executive and operational management and financial experience while holding key executive positions with several public companies in various industries.
In 1992 Mr. Lai founded and until December 2012 was the principal owner and President of Genesis Capital Group, Inc., which provided significant consulting services to many public and private companies in the powersports, technology and other industries, while advising its clients in corporate development, mergers and acquisitions, and private and public capital-raising through equity offerings. Mr. Lai’s role as a co-founder of the company and his many years of experience as a chief executive officer of many public or private companies are material factors regarding his qualifications to serve on our Board of Directors.
Mr. Ruben is the Managing Director of Life Sciences at Trinity Capital where he focuses on venture lending to healthcare companies. Mr. Ruben joined Trinity after 12 years of investment banking, most recently at RBC Capital Markets where he was Head of Life Science Tools and Diagnostics coverage.
He is a published expert in corporate finance with a background in economics. He holds degrees from Pomona College and Harvard Business School. Mr. Ruben’s long track record of successful experiences in analyzing life sciences companies, capital investments and his overall finance background including executing billions of dollars of M&A and securities transactions are material factors regarding his qualifications to serve on our Board of Directors.
Advisory Board
Tracy Turner
DVM
Tracy Turner began his professional career as a farrier and used those skills to help finance his education. He received his DVM degree from Colorado State University in 1978. He completed an internship at the University of Georgia and a surgical residency, as well as a Master of Science degree at Purdue University in 1981. His Master’s thesis was “Thermography of the Lower Limb of the Horse.” He served on the faculty of the Universities of Illinois, Florida and Minnesota. At Minnesota, he was Head of Large Animal Surgery and attained the rank of full Professor before leaving academics to join Anoka Equine Clinic in 2004.
Turner's primary research efforts have focused on equine lameness with particular interest in equine podiatry, back issues in horses, rehabilitation and thermography. His podiatry research has evaluated the radiographic and morphologic characteristics of hoof imbalance, as well as the differential diagnosis of palmar foot pain (PFP) and the development of PFP treatment strategies. Turner has researched the use of diagnostic imaging techniques for evaluation of equine back problems (including saddle fit) and developed epidemiological data on overriding spinous processes in horses. He pioneered the use of thermography as a diagnostic aid in lameness evaluation, as well as its use in horse welfare regulation. Turner has extensively published on these topics and been invited to lecture nationally and internationally.
Turner is a Diplomate of the American College of Veterinary Surgeons, a Diplomate of the American College of Sports Medicine and Rehabilitation, and a Fellow of the American Academy of Thermology. He is an active member of the AVMA, AAEP and the American Horse Council. Turner has served as chairman of the AAEP's Farrier Liaison Committee, served on the AAEP Foundation Advisory Council and the AAEP Educational Programs Committee. Presently, he is on the AAEP Board of Directors. He is a past president of the Minnesota Association of Equine Practitioners and a member of the Minnesota Veterinary Medical Association. He is a member of the board of directors of the Minnesota Horse Council and is currently the Minnesota Horse Council vice-president and chair for the Legislative and Horse Welfare committees. He is currently president of the American Academy of Thermology. He has consulted for United States Equestrian Federation, The USDA Horse Protection and Federation Equestrienne International (FEI). He has participated as an instructor at Equitarian Workshops in Mexico, Nicaragua and Costa Rica. He has participated in the Equitarian projects in Honduras and Costa Rica. He is married to veterinarian Julia Wilson and has two sons.
Sherman Canapp
DVM, MS, CCRT, DACVS, DACVSMR
Dr. Sherman Canapp, originally from Maryland, was the first to complete a combined DVM/MS at Kansas State University. Dr. Canapp then completed an internship in small animal medicine and surgery at the University of Missouri followed by a three-year residency in small animal surgery at the University of Florida.
Dr. Canapp is a Diplomate of the American College of Veterinary Surgeons and Charter Diplomate of the American College of Veterinary Sports Medicine and Rehabilitation, where he is Past President of the college.
He is currently the National Director of Sports Medicine, Rehabilitation and Regenerative Medicine for Thrive Pet Healthcare.
Dr. Canapp is the co-founder of the Veterinary Orthopedic & Sports Medicine Group (VOSM, where he treats sports related injuries, performs arthroscopic procedures and regenerative medicine treatments. His primary caseload is performance, sporting and working dogs.
Dr. Canapp is the President and CEO of Orthobiologic Innovations, LLC (OBI), a translational medicine company focused on product design, development, and testing of orthopedic and arthroscopic devices, instrumentations, medical systems, biologics, and regenerative medicine technologies. OBI also designs and performs clinical trials.
He created the VOSM Academy, LLC - educational training programs for veterinarians worldwide interested in bringing high level sports & regenerative medicine, diagnostic musculoskeletal ultrasound, and arthroscopic procedures to their practices. Certified practitioners/locations include Seattle, Philadelphia, Nashville, Jacksonville, Finland, Japan, and Australia.
Dr. Canapp established Project GO (Global Orthopedics For Animals), 501(c)(3), a non-profit foundation that funds orthopedic procedures for government working dogs, rescue and wildlife with musculoskeletal injuries. He is also the co-founder of Canapp Sports Medicine, LLC (CSM), which provides teleconsultations, telemedicine, and tele-training to veterinarians and performance dog owners around the world. CSM offers educational content and remote procedural assistance for the diagnosis and treatment of canine sports-related injuries.
He is a member of the Governing Board of Directors for the non-profit organization, Hart For Animals, Maryland, and a member of the Board of Trustees for Johns Hopkins Medicine, Howard County General Hospital, Maryland..